Traders should monitor upcoming sales figures for Exdensur in China and potential uptake dynamics, as this approval opens a large new market. Consider positioning ahead of respiratory segment earnings disclosures. Watch for NMPA decision on Exdensur for CRSwNP, which is under review.
GSK drugs
GSK drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 30 $54.23entry
- T+1 · 8mo ago +1.77%α −1.12% · $55.19
- T+5 · 7mo ago +2.97%α −1.33% · $55.84
- T+20 · 7mo ago +0.44%α −12.15% · $54.47
- T+60 · 5mo ago −4.32%α −20.81% · $51.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for the treatment of severe asthma with an eosinophilic phenotype in patients aged 12 and older. The approval is based on SWIFT-1 and SWIFT-2 phase III trials showing significant reductions in asthma exacerbations, with 58% and 48% lower annualized exacerbation rates versus placebo, respectively.
Key Facts
- Exdensur approved in China for severe asthma with eosinophilic phenotype in patients aged 12+
- Approval based on SWIFT-1 and SWIFT-2 phase III trials demonstrating 58% and 48% reduction in annualized exacerbation rates versus placebo
- Exdensur is the first and only ultra-long-acting biologic in China with twice-yearly dosing for this indication
- More than 2 million people in China suffer from severe asthma
- Exdensur already approved in the US, EU, UK, and Japan for severe asthma and/or CRSwNP
Financial Impact
Potential for meaningful revenue growth in a high-burden, underserved market; China represents a major commercial opportunity given 46M adults with asthma and limited biologic options
Risk Factors
- Commercial execution risk in China including pricing, reimbursement, and market access
- Competition from existing biologics despite Exdensur's twice-yearly dosing advantage
- Forward-looking statements include caution about actual results differing due to risks and uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-002916 |
| Document: 0001654954-26-002916-index-headers.html | 0001654954-26-002916 |
| Document: 0001654954-26-002916-index.html | 0001654954-26-002916 |
| Document: 0001654954-26-002916.txt | 0001654954-26-002916 |
Track record
64 reports on GSK
8 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers